OBJECTIVES: The aim of the study was to investigate the effect of microneedle (MN) pretreatment on the transdermal delivery of a model drug (Rhodamine B, Rh B) encapsulated in polylactic-co-glycolic acid (PLGA) nanoparticles (NPs) focusing on the MN characteristics and application variables. METHODS: Gantrez MNs were fabricated using laser-engineered silicone micro-mould templates. PLGA NPs were prepared using a modified emulsion-diffusion-evaporation method and characterised in vitro. Permeation of encapsulated Rh B through MN-treated full thickness porcine skin was performed using Franz diffusion cells with appropriate controls. KEY FINDINGS: In-vitro skin permeation of the nanoencapsulated Rh B (6.19 ± 0.77 µg/cm²/h) was significantly higher (P < 0.05) compared with the free solution (1.66 ± 0.53 µg/cm²/h). Mechanistic insights were supportive of preferential and rapid deposition of NPs in the MN-created microconduits, resulting in accelerated dye permeation. Variables such as MN array configuration and application mode were shown to affect transdermal delivery of the nanoencapsulated dye. CONCLUSIONS: This dual MN/NP-mediated approach offers potential for both the dermal and transdermal delivery of therapeutic agents with poor passive diffusion characteristics.
OBJECTIVES: The aim of the study was to investigate the effect of microneedle (MN) pretreatment on the transdermal delivery of a model drug (Rhodamine B, Rh B) encapsulated in polylactic-co-glycolic acid (PLGA) nanoparticles (NPs) focusing on the MN characteristics and application variables. METHODS: Gantrez MNs were fabricated using laser-engineered silicone micro-mould templates. PLGA NPs were prepared using a modified emulsion-diffusion-evaporation method and characterised in vitro. Permeation of encapsulated Rh B through MN-treated full thickness porcine skin was performed using Franz diffusion cells with appropriate controls. KEY FINDINGS: In-vitro skin permeation of the nanoencapsulated Rh B (6.19 ± 0.77 µg/cm²/h) was significantly higher (P < 0.05) compared with the free solution (1.66 ± 0.53 µg/cm²/h). Mechanistic insights were supportive of preferential and rapid deposition of NPs in the MN-created microconduits, resulting in accelerated dye permeation. Variables such as MN array configuration and application mode were shown to affect transdermal delivery of the nanoencapsulated dye. CONCLUSIONS: This dual MN/NP-mediated approach offers potential for both the dermal and transdermal delivery of therapeutic agents with poor passive diffusion characteristics.
Authors: Tarl W Prow; Jeffrey E Grice; Lynlee L Lin; Rokhaya Faye; Margaret Butler; Wolfgang Becker; Elisabeth M T Wurm; Corinne Yoong; Thomas A Robertson; H Peter Soyer; Michael S Roberts Journal: Adv Drug Deliv Rev Date: 2011-02-23 Impact factor: 15.470
Authors: Patrycja Mikolajewska; Ryan F Donnelly; Martin J Garland; Desmond I J Morrow; Thakur Raghu Raj Singh; Vladimir Iani; Johan Moan; Asta Juzeniene Journal: Pharm Res Date: 2010-07-31 Impact factor: 4.200
Authors: Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Kalpana S Paudel; Peter A Crooks; Nicole K Brogden; Mark R Prausnitz; Audra L Stinchcomb Journal: J Pharm Sci Date: 2010-07 Impact factor: 3.534
Authors: Ryan F Donnelly; Desmond I J Morrow; Francois Fay; Christopher J Scott; Sharif Abdelghany; Raghu Raj Thakur Singh; Martin J Garland; A David Woolfson Journal: Photodiagnosis Photodyn Ther Date: 2010-10-08 Impact factor: 3.631
Authors: Samiullah Khan; Muhammad Usman Minhas; Ismaiel A Tekko; Ryan F Donnelly; Raghu Raj Singh Thakur Journal: Drug Deliv Transl Res Date: 2019-08 Impact factor: 4.617
Authors: Yasmine A Gomaa; Martin J Garland; Fiona J McInnes; Ryan F Donnelly; Labiba K El-Khordagui; Clive G Wilson Journal: Eur J Pharm Biopharm Date: 2013-02-24 Impact factor: 5.571